Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1726
Broadwind
BWEN
$127M
| $4.92M | 0.01% |
976,290
+145,100
| +17% | +$921K |
|
1727
Ingles Markets
IMKTA
$1.65B
| $4.92M | 0.01% |
147,774
+113,000
| +325% | +$4.49M |
|
1728
CGI
GIB
$15.2B
| $4.91M | 0.01% |
96,100
-152,700
| -61% | -$7.46M |
|
1729
Nature's Sunshine
NATR
$266M
| $4.88M | 0.01% |
368,700
+2,700
| +0.7% | +$30.5K |
|
|
ESV
1730
DELISTED
Ensco Rowan plc
ESV
| $4.88M | 0.01% |
236,525
-1,475,222
| -86% | -$42.4M |
|
1731
Digi International
DGII
$3.23B
| $4.88M | 0.01% |
480,800
+60,600
| +14% | +$643K |
|
|
OMCC
1732
DELISTED
Old Market Capital Corp
OMCC
| $4.88M | 0.01% |
530,329
-14,500
| -3% | -$134K |
|
1733
Acco Brands
ACCO
$401M
| $4.88M | 0.01% |
418,747
-186,400
| -31% | -$2.32M |
|
|
ITI
1734
DELISTED
Iteris, Inc.
ITI
| $4.87M | 0.01% |
783,300
+92,200
| +13% | +$525K |
|
|
DRD
1735
DRDGold
DRD
$2.1B
| $4.87M | 0.01% |
1,544,770
-61,800
| -4% | -$233K |
|
|
WWE
1736
DELISTED
World Wrestling Entertainment
WWE
| $4.86M | 0.01% |
+238,800
| New | +$4.94M |
|
1737
Community Health Systems
CYH
$423M
| $4.86M | 0.01% |
+487,493
| New | +$4.46M |
|
|
GSB
1738
DELISTED
GlobalSCAPE, Inc.
GSB
| $4.85M | 0.01% |
916,290
+81,153
| +10% | +$357K |
|
1739
HealthEquity
HQY
$8.76B
| $4.84M | 0.01% |
97,100
+63,500
| +189% | +$2.97M |
|
1740
C&F Financial
CFFI
$287M
| $4.8M | 0.01% |
102,400
+5,900
| +6% | +$285K |
|
|
ADAP
1741
DELISTED
Adaptimmune Therapeutics
ADAP
| $4.8M | 0.01% |
1,069,300
+288,500
| +37% | +$1.51M |
|
|
NEFF
1742
DELISTED
Neff Corporation
NEFF
| $4.8M | 0.01% |
252,600
+34,300
| +16% | +$623K |
|
|
XBKS
1743
DELISTED
Xenith Bankshares, Inc. Common Stock
XBKS
| $4.75M | 0.01% |
153,026
+63,400
| +71% | +$1.81M |
|
1744
G. Willi-Food International
WILC
$400M
| $4.74M | 0.01% |
623,300
+6,700
| +1% | +$43.9K |
|
|
NTUS
1745
DELISTED
Natus Medical Inc
NTUS
| $4.74M | 0.01% |
126,962
-22,332
| -15% | -$807K |
|
1746
3D Systems Corp
DDD
$616M
| $4.73M | 0.01% |
+252,850
| New | +$4.79M |
|
|
SPA
1747
DELISTED
Sparton
SPA
| $4.72M | 0.01% |
214,835
+36,200
| +20% | +$714K |
|
|
RYZ
1748
Ryerson Holding Corp
RYZ
$1.5B
| $4.69M | 0.01% |
473,400
-285,100
| -38% | -$3.03M |
|
1749
Build-A-Bear
BBW
$481M
| $4.68M | 0.01% |
448,300
-48,200
| -10% | -$491K |
|
|
SYNC
1750
DELISTED
Synacor, Inc.
SYNC
| $4.67M | 0.01% |
1,279,000
+118,400
| +10% | +$421K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.